The potency and mechanism of ACACA inhibition by soraphen A strongly suggest that pharmacological targeting of the soraphen A binding subunit dimerization site (i.e., the biotin carboxylase (BC) domain of the enzyme) may be useful to identify potent, efficacious ACACA inhibitors for cancer intervention. Here, MCCC2 is linked to cancer.